Issued by Pepceuticals Limited
SEAL OF APPROVAL FOR PEPCEUTICALS
MHRA accreditation seals future growth plans
UK pharmaceutical manufacturer, Pepceuticals, has been given MHRA approval for the manufacture of APIs following an additional £2 million investment in new premises and state-of-the-art manufacturing facilities in Leicestershire, UK. Pepceuticals is now the largest peptide cGMP manufacturer in mainland UK and is the Research Council UK (RCUK) preferred supplier of peptides and antibodies.
The 10,000 sq ft industrial unit has been equipped with eight large and medium sized, high-tech cGMP laboratories, enabling Pepceuticals to offer a versatile service to support research and in-process projects; from pre-clinical toxicology studies through to early stage clinical trials and eventually to full manufacturing capacity of approved APIs for larger clinical trials.
Managing Director, Dr Kamal Badiani, who founded the company 13 years ago, said: “We are absolutely delighted that our investment and hard work has culminated in this vital approval. The peptide industry is booming and we have been achieving 20% year on year growth for the past two years. We now have the capacity and capability to deliver a complete chemistry manufacturing solution to the pharmaceutical industry.”
Since gaining MHRA approval, Pepceuticals has already boosted staff numbers with the appointment of a new Head of Sales, Daniel Milek who will be responsible for opening up new trade opportunities with universities, pharmaceutical manufacturers and research bodies. Daniel was previously employed as a Project Leader at Thermo Fisher Scientific in Loughborough.
The facilities at the Leicestershire base are continuing to be enhanced and have recently included the installation of a Quatro Premier Xe Mass Spectrometer, a Synapt G1 High Definition Mass Spectrometer, 2 Symphony® 12-channel peptide synthesisers and an Overture™ Robotic Peptide Library Synthesizer.
The company is currently awaiting a further decision from the MHRA on its application for a Specials Licence, allowing the firm to manufacture unlicensed products for use in early studies and clinical trials. The license would be one of only a handful issued in the UK.
ENDS
Editors’ Notes
Media contact:
Louise Third – Integra Communications Limited
Tel: 0115 912 4350 / 07773 288342
louise@integracommunications.co.uk
About Pepceuticals Limited
Pepceuticals Limited is a manufacturer of synthetic peptides, is dedicated to supplying the Life Science industry with a high quality custom peptide and antibody service. In addition, it is able to offer an extensive range of catalogue peptides and a wide range of reagents used for the synthesis of peptides.
Pepceuticals Limited was formed in Newarke Street, Leicester in 1998 by Dr Kamal Badiani. Dr Badiani, who has a doctorate in medicinal chemistry, moved the company to Beaumont Leys (using a laboratory in New Orleans) before relocating to a 2,000 sq ft property in BioCity Nottingham in 2OO4
Due to continued expansion, Pepceuticals moved into the new site in Enderby in December 2010.
Pepceuticals recently won a five-year contract worth £400,000-500,000 a year with the Research Councils of the UK, which encompasses organisations including the Medical Research Council, and the Biotechnology and Biological Sciences Research Council.
Pepceuticals Ltd
4 Fieldspar Close
Warrens Park
Enderby
Leicestershire LE19 4JS
Tel: +44 (0)116 284 9301
Fax: +44 (0)116 286 2464
Website: www.pepceuticals.co.uk
Email: peptides@pepceuticals.co.uk